Inpeco partnering with QIAGEN and Diasorin to launch new fully automated QuantiFERON latent TB testing workflow

• Confirms Inpeco’s mission to advance healthcare through lab automation systems that reduce manual intervention and support reliable test results for patients 

• Fully automated workflow targeted for late 2027 launch integrates QIAGEN QuantiFERON test, Diasorin LIAISON systems, and dedicated end-to-end automation solution from Inpeco 

• Seamless automation of all QuantiFERON testing steps helps laboratories increase efficiency, turnaround time, and test result quality – with full sample traceability

Novazzano, Switzerland, May 7, 2026 – Inpeco SA, the global leader in Total Laboratory Automation, today announced a partnership with QIAGEN and Diasorin to develop a track-based solution that automates all steps of the QuantiFERON IGRA testing workflow. Leveraging Inpeco’s flagship automation technology FlexLab™ X, the new solution will seamlessly integrate QIAGEN’s QFT tubes and Diasorin’s LIAISON analyzers into a touchless, high-throughput workflow with end-to-end sample traceability, supporting reliable test results for optimal patient outcomes.

Planned for launch in late 2027, this new workflow is designed for customers using Diasorin LIAISON systems aiming to automate the complete latent TB testing process without manual operator intervention, from preanalytical tube handling and incubation with Inpeco to detection on LIAISON systems.

In this partnership with QIAGEN and Diasorin, Inpeco will develop two purpose-built innovations, a dedicated QuantiFERON aliquoting system and an intelligent incubation system, which will be fully integrated into the FlexLab™ X track to enable a seamless end-to-end automated workflow.

By enabling full automation of the QuantiFERON IGRA workflow, laboratories can decouple volume growth from staffing requirements, reduce hands-on time by up to 80% and transition to continuous, real-time processing. These capabilities are expected to significantly improve turnaround time, operational efficiency and scalability for high-throughput laboratories and larger testing networks.

“Automation is essential for laboratories facing growing testing volumes and ongoing workforce constraints,” said Riccardo Triunfo, CEO of Inpeco. “We welcome this collaboration with QIAGEN and Diasorin to connect advanced track-based laboratory automation with a leading latent TB testing workflow. By bringing together sample routing, analyzer connectivity, sample traceability and workflow monitoring around QuantiFERON-TB testing on LIAISON systems, we aim to help laboratories expand high-throughput testing capacity and contribute to the global fight against tuberculosis.”

“Latent TB testing is moving toward higher-volume, more automated workflows as the market increasingly shifts from traditional skin testing to modern IGRA-based detection,” said Thierry Bernard, CEO of QIAGEN. “By combining QuantiFERON’s CD4 and CD8 data foundation with LIAISON-based testing, Inpeco automation for higher-throughput laboratories and AI-enabled risk stratification designed to support all QuantiFERON workflows, we are building a Sample to Insight ecosystem to help customers scale testing efficiently while improving consistency, traceability and confidence in results.”

“We are seeing positive customer feedback on the new LIAISON chemistry for latent TB detection using QuantiFERON tubes, particularly around speed, throughput and workflow efficiency,” said Carlo Rosa, Chief Executive Officer of Diasorin. “Working together with QIAGEN and Inpeco, we are building on that momentum to create a differentiated solution for high-throughput customers. By combining QIAGEN QuantiFERON technology, Diasorin LIAISON platforms and Inpeco automation capabilities, we can help laboratories test more patients per hour, reduce hands-on time, strengthen traceability and deliver faster results in support of TB prevention.”

Download the Media Release: “Inpeco partnering with QIAGEN and Diasorin to launch new fully automated QuantiFERON latent TB testing workflow”

 About Inpeco

Inpeco is the global leader in Total Laboratory Automation. The company’s game-changing solutions combine open connectivity with full sample traceability to support secure test results and increased productivity in clinical laboratories around the world. To date, more than 2,800 Inpeco systems have been shipped to 78 countries. Inpeco also develops automation solutions for anatomical pathology labs, blood banks, and life science applications. The Group is headquartered in Novazzano, Switzerland, and operates a development and manufacturing facility in Italy, as well as sales and service offices in Europe, the United States and China. For more information, please visit: www.inpeco.com

Public Relations

e-mail: Marketing@Inpeco.com 

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences and Molecular Diagnostics. As of March 31, 2026, QIAGEN employed approximately 5,600 people across more than 35 locations. For more information, visit www.qiagen.com